Targetrin Therapeutics

Targetin Therapeutics is a biotechnology company focused on the development of novel Retinoid X Receptor (RXR) selective ligands, known as rexinoids, for oncology applications. Spun out from the University of Alabama at Birmingham (UAB), the company aims to address the limitations of existing retinoid therapies by creating compounds with improved safety profiles and higher specificity. Their lead candidate, 9-cis-UAB30, has been investigated in Phase 1 clinical trials for the prevention of breast cancer and has shown promise in various solid tumor models. The company's research platform leverages deep expertise in medicinal chemistry to target RXR-mediated signaling pathways that regulate cell growth and differentiation. Targetin Therapeutics continues to collaborate with academic and federal institutions to advance its pipeline of small molecule rexinoids toward clinical commercialization.